Sartorius Stedim Biotech (STU:56S1) EPS (Basic): €2.75 (TTM As of Mar. 2026)


STU:56S1 Sartorius Stedim Biotech SA STU:56S1
82 GF Score
Price €163.50
GF Value €208.96
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech EPS (Basic)?

Sartorius Stedim Biotech STU:56S1 +0.37% 82 EPS (Basic) is €2.75 as of Mar. 2026. GuruFocus rates STU:56S1 with a GF Score™ of 82/100 and a GF Value™ of €208.96 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Sartorius Stedim Biotech's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.91. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €2.75.

Sartorius Stedim Biotech's EPS (Diluted) for the three months ended in Mar. 2026 was €0.91. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €2.75.

Sartorius Stedim Biotech's EPS without NRI for the three months ended in Mar. 2026 was €0.91. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 2.75.

During the past 12 months, Sartorius Stedim Biotech's average EPS without NRIGrowth Rate was 30.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was -30.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -15.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Sartorius Stedim Biotech's highest 3-Year average EPS without NRI Growth Rate was 82.90% per year. The lowest was -30.40% per year. And the median was 24.80% per year.

Sartorius Stedim Biotech  (STU:56S1) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sartorius Stedim Biotech EPS (Basic) Related Terms

Sartorius Stedim Biotech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech EPS (Basic) Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.50 9.51 3.37 1.81 2.73

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.69 0.66 0.49 0.91
STU:56S1
82GF Score
Sartorius Stedim Biotech SA STU:56S1
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sartorius Stedim Biotech's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(265.6-0)/97.296
=2.73

Sartorius Stedim Biotech's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(88.1-0)/96.813
=0.91

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €2.75 mean?
Sartorius Stedim Biotech (STU:56S1) has a EPS (Basic) of €2.75 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's EPS (Basic) too high?
Sartorius Stedim Biotech's current EPS (Basic) is €2.75. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's EPS (Basic) compare to ISRG and BDX?
Sartorius Stedim Biotech's EPS (Basic) of €2.75 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current EPS (Basic) is €2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (STU:56S1) is currently considered Modestly Undervalued. The stock's GF Value™ is €208.96, compared to a current price of €163.50 — trading 21.8% below its estimated fair value. The current EPS (Basic) is €2.75. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Sartorius Stedim Biotech (STU:56S1), the current EPS (Basic) is €2.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (STU:56S1) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €163.50 is trading 21.8% below its estimated GF Value™ of €208.96. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for STU:56S1:

  • EPS (Basic): €2.75
  • GF Value™: €208.96 vs. price of €163.50 (21.8% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the STU:56S1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score

Get the complete analysis for STU:56S1

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€163.50
Price
€208.96
GF Value